Dear Sir, Pursuant to Regulation 47(3) of SEBI(LODR), Regulation,2015. Please find the News Paper clipping towards our Published of our Quarterly Results for the period ended on 30-9-2025. ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Colinz Laboratories has filed the newspaper clipping of its Un-Audited Financial Results for the quarter and half year ended 30-Sep-2025, as published in Free Press Journal and Navshakti on 4-Nov-2025, with the Board having approved these results on 3-Nov-2025. Revenue from Operations for Q2 FY26 stood at Rs. 154.73 lakhs, down about 20% from Rs. 194.08 lakhs in Q2 FY25, while H1 FY26 revenue was Rs. 318.86 lakhs versus Rs. 375.47 lakhs in H1 FY25. Net Profit after Tax for Q2 FY26 was Rs. 14.05 lakhs (vs Rs. 15.57 lakhs YoY) and H1 FY26 PAT was Rs. 25.97 lakhs (vs Rs. 29.29 lakhs YoY), though profit improved sequentially from Q1 FY26 (Rs. 11.92 lakhs). Basic and Diluted EPS for Q2 was Rs. 0.56 (vs Rs. 0.62 YoY) and H1 EPS was Rs. 1.03 (vs Rs. 1.16 YoY). Statutory auditors have issued an unqualified opinion on the results.
Both top-line and bottom-line declined year-on-year for the quarter and half year, indicating weaker operating performance versus the prior year, though a sequential improvement in profit from Q1 offers a small positive signal. Short-term stock sentiment may be mildly negative given the YoY contraction in revenue and earnings.